The FIT-001 Phase 1a/1b study of darlifarnib plus cabozantinib in advanced RCC demonstrated durable antitumor activity, with ORR of 33–50% and mPFS of 13 months in cabozantinib-naive patients. Safety was manageable, and dose optimization is ongoing for future Phase 3 trials.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.